Q32 Bio Inc (QTTB) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Q32 Bio Inc   (NASDAQ: QTTB)


Q32 Bio Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Q32 Bio Inc's ROI in the third quarter of 2026?
Q32 Bio Inc achieved a return on average invested assets (ROI) of 25.26 % in its third quarter of 2026, this is above QTTB's average return on investment of -34.41%.
Q32 Bio Inc invested over the 12 months ending in its third quarter of 2026 $128 million

ROI fell compared to the second quarter of 2026, despite the net income growth of % from the second quarter of 2026.

Within the Healthcare sector 10 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 75, from total ROI ranking in the second quarter of 2026 at 102.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 114.85 % -3.86 % -35.24 % -41.68 % 102.34 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 293 111 57 50 47
Return On Investment (TTM) 25.26 % 51.04 % 63.78 % 55.18 % -70.83 %
QTTB's Overall Ranking # 75 # 102 # 3999 # 4072 # 4113
Seq. Investment Change TTM 92.9 % 27.02 % -3.57 % -9.07 % -13.68 %
Seq. Net Income Change TTM -4.54 % 1.63 % 11.48 % - -
Net Income (TTM) in Millions 32 34 33 30 -42

QTTB Company Profile >> Back to QTTB Roi Comparisons >> See Annual QTTB Return On Investment



Return On Investment QTTB's Ranking
Within: No.
Industry # 6
Sector # 11
Overall # 75

Return On Investment Statistics
High Average Low
58.17 %
-34.41 %
-146.78 %
(Mar 31 2026)   (Sep 30 2024)







Financial Statements
Q32 Bio Inc's III. Quarter Investments $ 293 Millions QTTB's Balance sheet
Q32 Bio Inc's III. Quarter Income $ -9 Millions Quarterly QTTB's Income Statement
QTTB's Income by Division See QTTB's Income by Division


QTTB Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 45 70 73 178 194
Y / Y Investment Growth -35.23 % -3.78 % -58.99 % -8.49 % -19.32 %
Net Income in Millions 30 -48 -113 -5 -96
Y / Y Net Income Growth - - - - -
Annual Return On Investment 65.56 % -67.97 % -154.76 % -2.81 % -49.24 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 65.56 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
QTTB's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for QTTB's Competitors
Subscribers only: Roi for Q32 Bio Inc's Suppliers
Subscribers only: Return On Investment for QTTB's Customers

Other Ratios
QTTB's Roa QTTB's Inventory Turnover Ratio QTTB's Growth Rates QTTB's Dividend Statistics
QTTB's Profitability Ratios QTTB's Asset Turnover Ratio QTTB's Dividend Growth
QTTB's Roe QTTB's Valuation Ratios QTTB's Financial Strength Ratios QTTB's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Ironwood Pharmaceuticals inc   68.68 %
Rigel Pharmaceuticals Inc  68.50 %
Alnylam Pharmaceuticals Inc   63.14 %
Idexx Laboratories Inc  52.51 %
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %

Date modified: 2026-11-05T10:10:18+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.